The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 16, 2022
Filed:
May. 30, 2018
Applicant:
Mission Therapeutics Limited, Cambridge, GB;
Inventors:
Martin Lee Stockley, Cambridge, GB;
Mark Ian Kemp, Cambridge, GB;
Andrew Madin, Cambridge, GB;
Michael David Woodrow, Cambridge, GB;
Assignee:
MISSION THERAPEUTICS LIMITED, Cambridge, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 403/12 (2006.01); C07D 207/14 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 498/04 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); C07D 207/14 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01);
Abstract
The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).